4-(吗啉磺酰)苯胺 | 21626-70-0

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(吗啉磺酰)苯胺
• 中文别名: 4-(吗啡琳磺酰)苯胺；4-(4-吗啉磺酰)苯胺
• 英文名称: 4-(morpholinosulfonyl)aniline
• 英文别名: 4-(morpholine-4-sulfonyl)phenylamine；4-(morpholine-4-sulfonyl)aniline；4-(morpholin-4-ylsulfonyl)aniline；4-morpholin-4-ylsulfonylaniline
• CAS: 21626-70-0
• 化学式: C₁₀H₁₄N₂O₃S
• mdl: MFCD00277213
• 分子量: 242.299
• InChiKey: FTKHPQFFQRKOJC-UHFFFAOYSA-N

物化性质

• 熔点：
  216 °C
• 沸点：
  442.1±55.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  81
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2935009090
• 储存条件：
  2-8°C

SDS

Name:	4-(Morpholinosulfonyl)aniline 97% Material Safety Data Sheet
Synonym:
CAS:	21626-70-0

Section 1 - Chemical Product MSDS Name:4-(Morpholinosulfonyl)aniline 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
21626-70-0	4-(Morpholinosulfonyl)aniline	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 21626-70-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 214 - 216 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H14N2O3S
Molecular Weight: 242

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, bases, reducing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 21626-70-0: QD7450000 LD50/LC50:
Not available.
Carcinogenicity:
4-(Morpholinosulfonyl)aniline - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 21626-70-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 21626-70-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 21626-70-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(吗啉磺酰)苯胺 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-bromo-4-(morpholine-4-sulfonyl)-phenylamine
  参考文献：
  名称：

  Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

  摘要：

  Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.061
• 作为产物：
  描述：

  N-乙酰苯胺 在 吡啶 、 氯磺酸 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 7.5h， 生成 4-(吗啉磺酰)苯胺
  参考文献：
  名称：

  新型萘醌4-氨基苯磺酰胺/羧酰胺衍生物作为蛋白酶体抑制剂的设计，合成及生物学评价

  摘要：

  设计，合成和评估了一系列带有萘醌药效团的新颖的4-氨基苯磺酰胺/羧酰胺衍生物，它们对人乳腺癌细胞系（MCF-7）的蛋白酶体抑制和抗增殖活性。通过光谱和元素分析证实了合成化合物的结构。使用基于细胞的测定法进行蛋白酶体抑制活性的研究。抗蛋白酶体活性结果表明，大多数化合物对半胱天冬酶样（CL，β1亚基），胰蛋白酶样（TL，β2亚基）和胰凝乳蛋白酶样（ChT-L，β5亚基）活性具有不同百分比的抑制活性。蛋白酶体。在测试的化合物中，化合物14在磺酰胺基团的氮原子上带有5-氯-2-吡啶基环的化合物是该系列中活性最高的化合物，显示出更高的抑制作用，对ChT-L的IC 50值为9.90±0.61、44.83±4.23和22.27±0.15μM，与铅化合物PI-083相比，蛋白酶体的CL和TL活性（IC 50分别 为12.47±0.21、53.12±2.56和26.37±0.5μM）。的抗增殖活性也通过MTT（3-（4

  DOI：

  10.1016/j.ejmech.2020.112890
• 作为试剂：
  描述：

  4-(吗啉磺酰)苯胺 、 Se-methyl-L-selenocysteine 在 4-(吗啉磺酰)苯胺 作用下， 生成 5-氯-2-(5-氯噻吩-2-磺酰基氨基)-N-(4-(吗啉-4-磺酰基)苯基)苯甲酰胺
  参考文献：
  名称：

  Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them

  摘要：

  本发明涉及式I的化合物，其中A1，A2，R1，R2，R3，X和n如权利要求中所定义，这些化合物是有价值的药物活性化合物，用于治疗和预防疾病，例如心血管疾病，如高血压，心绞痛，心力衰竭，血栓或动脉硬化。式I的化合物能够调节体内环磷酸鸟苷单磷酸（cGMP）的产生，并且通常适用于与cGMP平衡紊乱有关的疾病的治疗和预防。此外，本发明还涉及制备式I的化合物的方法，它们用于治疗和预防上述疾病以及制备用于此目的的药物，以及包含式I的化合物的制药制剂。

  公开号：

  US06881735B2

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] NOVEL TETRAHYDROQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS INÉDITS DE LA TÉTRAHYDROQUINOLINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012101068A1

  公开（公告）日：2012-08-02

  A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1 to R8, A1 to A3 have the significance given in claim 1, can be used as AMPK modulators for treating obesity, hyperglycemia or type 2 diabetes.

  化合物的化学式（I）或其药用可接受的盐或酯，其中R1至R8，A1至A3具有权利要求1中给定的含义，可用作AMPK调节剂，用于治疗肥胖症、高血糖或2型糖尿病。
• Highly efficient one-pot synthesis of α-aminophosphonates using nanoporous AlSBA-15 catalyst in a three-component system
  作者：Murali Krishna Kolli、Elamathi Palani、Chandrasekar Govindasamy、Vishweshwar Rao Katta

  DOI：10.1007/s11164-018-3458-1

  日期：2020.2

  range of 480 to 757 m2/g and 0.65 to 0.95 cm3/g, respectively. The catalytic performance of nanoporous AlSBA-15 catalysts are used as an outstanding catalytic system for one-pot synthesis of α-aminophosphonates via Kabachnik-Fields reaction in a three-component system using amines (primary/secondary), carbonyl compounds (aldehydes/ketones) and diethyl phosphite. The major advantages of the present

  使用水热法合成了具有不同n Si / n Al比（41、129和210）的纳米多孔AlSBA-15催化剂。这些催化剂通过XRD，N 2吸附，TPD-NH 3，FT-IR，SEM和TEM表征。AlSBA-15催化剂的XRD分析证实，存在具有p6mm对称性的井井有条的晶体结构。比表面积和AlSBA-15的催化剂的比孔体积是在480 757 m的范围内2 /克和0.65〜0.95厘米3/ g。纳米多孔AlSBA-15催化剂的催化性能被用作出色的催化体系，用于在三组分体系中使用胺（伯/仲），羰基化合物（醛/酮）通过Kabachnik-Fields反应一锅合成α-氨基膦酸酯。 ）和亚磷酸二乙酯。本发明的主要优点是优异的收率，短的反应时间，简单的实验技术，高的化学选择性，催化剂可回收性，易于处理的程序和绿色方法。α-氨基膦酸酯的三组分合成是首先由胺和醛/酮形成亚胺，然后添加磷酸盐。实验结果表明，纳米多
• [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
  申请人：INCYTE CORP

  公开号：WO2009064835A1

  公开（公告）日：2009-05-22

  The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)

  本发明提供了取代的双环杂环芳基化合物，包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺，这些化合物调节激酶的活性，在治疗与激酶活性相关的疾病方面具有用处，例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式：(1)